An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors
Conditions
Colon | Esophagus | Liver | Pancreas
Phase II
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.
- Trial withMerck Sharp & Dohme
- Start Date08/02/2022
- End Date07/07/2026
For more information about this study, contact:
Jessica Goepfert
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
- Last Updated08/10/2022
- Study HIC#2000031535